Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00337103 · ClinicalTrials.gov registry record · Phase 3
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,276
- Enrollment target
NCT00337103 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 1,276 participants.
The verdict
NCT00337103, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,276 participants
- Enrollment target
Study Summary
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capecitabine on a one-to-one ratio.
Interventions
- DRUG Capecitabine
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,276 participants |
| Start Date | 2006-09-20 |
| Est. Completion | 2017-12-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00337103
The ClinicalTrials.gov registry entry for NCT00337103 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capecitabine is the first listed.
NCT00337103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00337103 about?
NCT00337103 is a clinical study titled "E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes". The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy. This is an open-label, randomized, two-parallel arm study. Patients will be randomized to receive either E7389 or capeci...
What is the current status of trial NCT00337103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,276 participants. The study started on 2006-09-20. Estimated completion is 2017-12-11.
What interventions are being tested in trial NCT00337103?
The interventions under investigation include: Capecitabine (DRUG), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT00337103?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.